Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Targeted cancer drugs are tested through a staged process that starts with laboratory and animal studies, proceeds through carefully monitored human trials, and ends with FDA review of evidence for a specific cancer indication and patient population. A first-in-human study usually focuses on how the drug behaves in people, what doses can be given, and which side effects occur; it is not designed to prove that the treatment works for everyone.
Biomarkers can narrow enrollment to tumors with a relevant molecular feature, sometimes using a companion diagnostic. Later trials test whether the drug produces meaningful clinical benefit compared with available care. FDA approval means that, for the labeled use, the evidence supports a favorable benefit–risk balance—not that every tumor with a related feature will respond.
As an Amazon Associate I earn from qualifying purchases.
Recommended Free Tools
What happens before a targeted cancer drug is given to a person?
Development begins with a proposed biological target, such as a mutated protein, fusion, amplified gene, or signaling pathway that appears to help a tumor grow or survive. Researchers first study whether changing that target affects cancer cells and whether a candidate drug reaches the tissues and produces the intended biological effect.
Nonclinical work generally includes laboratory experiments and animal studies. These studies can provide information about pharmacology, toxicology, dose ranges, metabolism, and potential organ risks. They cannot establish how well the drug will treat people, but they supply the safety and dosing rationale needed for a human study.
Popular on Amazon
- 【90 Degree Full Function USB C Adapter】Supports the latest USB4 standard for up to 40Gbps of bandwidth, 8K video support, and up to 240W Fast charging; Support USB PD 3.1 Extended Power Range (EPR) including 140W, 180W and 240W. Your productivity is easily doubled. *Warm Tip: For the best fit, please make sure the USB-C port is fully exposed; thick or bulky cases may affect compatibility.
- 【Reliable Quality】Made from high-quality, scratch-resistant aluminum alloy, delicate metal frame. get excellent wear resistance and heat dissipation. Non-Slip Design for easier insertion and removal.
- 【Small and portable】Ultra thin size, ultra compact design, a petite physique that matches the minimalist design of your modern laptops. Coming with a slim figure that won't block the port next to the one it's plugged into.
- 【Compatibility】Widely work with most usb c, thunderbolt 4/3 devices. Compatibilit for ROG Ally, Steam Deck, Switch, MacBook Pro, Quest 3 VR headset, Surface Book 2, iPhone 18/17/16/15, Samsung Galaxy S23/S22/S21, Note 20/10, Google Pixel, ChromeBook, etc.
- 【Excellence Customer Support】If you experience any issues or cable failure, simply reach out to our dedicated customer service team. We provide a prompt response within 18 hours, providing you with the necessary technical support to resolve any concerns.
Before a sponsor starts clinical testing in the United States, it submits an investigational new drug (IND) application to FDA. The submission describes the manufacturing process, nonclinical findings, proposed protocol, investigator qualifications, and plans for monitoring safety. FDA’s drug-development definitions explain how this transition from nonclinical work to human research fits into the broader review system.
An IND does not mean FDA has concluded that the drug is effective. It permits the proposed investigation to proceed when the available information supports exposing participants to the study drug under the protocol’s protections.
What is a first-in-human cancer trial?
A first-in-human trial is the initial study in people. In oncology, these studies commonly enroll patients who have cancer rather than healthy volunteers, because the drug may have substantial toxicity and the ethical balance differs when participants have advanced disease with limited treatment options.
FDA describes Phase 1 as an initial human introduction that emphasizes pharmacology, pharmacokinetics, dose-related effects, and side effects. Investigators may begin at a dose supported by nonclinical findings and then increase doses in successive groups, using predefined safety rules. The goal is to identify doses and schedules that can be studied further, not to establish a final response rate.
What investigators measure in Phase 1
- Safety and tolerability: which adverse events occur, how severe they are, when they appear, and whether they resolve after a dose change or treatment interruption.
- Pharmacokinetics: how quickly the drug is absorbed, distributed, metabolized, and eliminated, including blood-concentration patterns over time.
- Pharmacodynamics: whether the expected biological effect is visible, such as suppression of a pathway or a change in a molecular marker.
- Dose and schedule: how much drug and how often it can be administered while maintaining an acceptable safety profile.
- Early antitumor activity: tumor shrinkage or disease control may be recorded, but observations from a small, early study do not by themselves prove durable clinical benefit.
Phase labels do not impose one universal design. Some programs use dose escalation followed by one or more expansion cohorts; others combine several disease groups or biomarker-defined groups in a single protocol. FDA’s guidance on expansion cohorts in first-in-human oncology trials describes expansion as an option for exploring activity in selected populations after initial dose-finding, not a mandatory feature.
How do biomarkers determine who enters a targeted-therapy trial?
A biomarker is a measurable characteristic that can indicate whether a tumor has the biological feature a drug is intended to affect. In a targeted-drug program, the biomarker may define eligibility, support a subgroup analysis, or help explain why responses differ among participants.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Eligibility testing can use DNA sequencing, RNA testing, protein staining, chromosome analysis, or another validated assay, depending on the target. The assay must be specified clearly enough that investigators know which results qualify a participant. A tumor may carry a nominally relevant alteration but still lack the level, location, or functional activity needed for the drug to work.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
When a test is essential for selecting patients for a drug, the test may be developed as a companion diagnostic. FDA’s oncology materials explain that the Center for Devices and Radiological Health reviews companion diagnostics in coordination with the drug review team. The drug label and diagnostic labeling can therefore be linked: one identifies the treatment indication, while the other describes how the relevant patient group is identified.
Why a biomarker is not a guarantee of response
Biology is more complicated than a single test result. Tumors can contain several subclones, lose or change a target over time, activate bypass pathways, or develop resistance after an initial response. The same alteration can also have different effects in different cancer types. For that reason, a trial’s cancer type, treatment line, assay, cutoff, and other eligibility rules are as important as the name of the biomarker.
Early targeted-drug studies may enroll a broad range of solid tumors, then open expansion cohorts for a particular cancer or biomarker group when initial data suggest a signal. Such cohorts can improve the precision of later estimates, but they remain subject to the limitations of their size, follow-up, and design.
What does Phase 2 test?
Phase 2 studies seek preliminary evidence that the drug works for a defined indication while continuing to characterize short-term adverse effects and risks. The population is usually more focused than in dose escalation, often by cancer type, treatment setting, biomarker, or dose selected from Phase 1.
Endpoints can include objective response rate, duration of response, progression-free survival, disease-control measures, patient-reported outcomes, or other prespecified outcomes. A response rate can show that tumors shrink, but the clinical importance depends on how long responses last, whether symptoms improve, and how the results compare with available treatments.
Phase 2 designs vary. A study may be single-arm when the disease setting is uncommon or the expected effect is large, or randomized when a concurrent comparison is feasible. The protocol should specify the imaging schedule, response criteria, analysis population, handling of missing scans, and follow-up needed to interpret durability.
FDA’s guidance on clinical trial endpoints for cancer-drug approval explains why endpoint choice must match the question being asked. A biological signal can justify further development without proving that patients live longer or feel better.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
How is Phase 3 different from earlier testing?
Phase 3 expands the evidence needed to assess overall benefit and risk and to support product labeling. These studies often enroll more participants and use a design intended to compare the investigational treatment with an available therapy, standard care, or another prespecified control.
A randomized controlled trial is especially informative because randomization helps balance known and unknown prognostic factors between groups. FDA’s March 2023 draft guidance on oncology trials supporting accelerated approval states that randomized controlled trials are preferred when feasible because they enable a more robust assessment of safety and efficacy and a direct comparison with available therapy. The document is draft, nonbinding guidance; it describes FDA’s stated recommendation rather than a universal legal requirement.
Phase 3 may examine a clinically meaningful endpoint such as overall survival, symptomatic progression, or a validated measure of quality of life. It can also confirm the magnitude and durability of an effect seen earlier, identify uncommon toxicities, and show whether benefits and harms differ across clinically relevant subgroups.
Phase 1, 2, and 3 are useful evidence categories, not rigid boxes with identical patient counts or a guaranteed sequence. A program can use adaptive designs, combine phases, add cohorts, or move directly to a later-stage randomized study when the disease context and preliminary evidence justify it.
How are tumor shrinkage and other endpoints interpreted?
Investigators distinguish between an endpoint that shows an effect quickly and one that demonstrates lasting clinical benefit. Tumor shrinkage is a direct observation of tumor burden, but it may be temporary, may not relieve symptoms, and may not reflect changes in every lesion. Duration of response adds an important time dimension.
Progression-free survival measures the time until disease progression or death under a defined analysis plan. Overall survival measures time until death and is less vulnerable to some forms of assessment bias, but it can require longer follow-up and can be affected by treatments received after progression. Patient-reported symptoms and quality-of-life measures address benefits that scans alone cannot capture.
Under the accelerated-approval pathway, FDA may rely on a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit when the statutory and regulatory requirements are met. FDA’s table of surrogate endpoints used as a basis for approvals illustrates that such endpoints are used in defined regulatory contexts, not as a blanket substitute for every clinical outcome.
Also popular on Amazon
- Portable and powerful USB-C HUB: BENFEI USB Type-C HUB, with super-soft and knot-free silicone woven design cable, meets most mobile office needs. Compact, lightweight, stylish, and powerful portable USB C Hub equipped with 1 x HDMI port, 1 x 100W charging, and 3 x USB ports. 18-month warranty, 24-hour response, to ensure you feel at ease when using our product.
- Design centered on comfort and reliability: Thanks to BENFEI's end-to-end in-house cable production capability, in-house PCBA and assembly capability, using the industry's most advanced silicone woven design and process, 20cm cable in length, no knots, super-soft, the HUB is easy to use in all scenarios: laptop, tablet, stand etc. Super-soft, 25000+ life cycles, to meet your daily carrying and office needs.
- 100W Charging: Support up to 90W USB C pass-through charging via Type-C port to keep your laptop powered. 10W is reserved for other interface operations. No data and video function on the Type-C port.
- 4K HDMI Display: The HDMI port supports media display at resolutions up to 4K 30Hz, keeping every incredible moment detailed and ultra vivid. Please note that the C port of the Host device needs to support video output.
- Transfer Files in Seconds: Transfer files and from your laptop at speeds up to 10 Gbps with USB A 3.2 port. Extra 2 USB A 2.0 ports are perfectly for your keyboards and mouse.
An accelerated approval therefore carries uncertainty about the ultimate clinical benefit. Confirmatory testing is required to verify benefit. If later evidence does not confirm benefit, the indication can face additional regulatory action under the applicable process. Accelerated approval should be described as a route to earlier availability based on a predictive endpoint, not as proof that all important outcomes are already established.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11What does FDA approval mean for a targeted cancer drug?
FDA review weighs the total evidence and asks whether the drug’s benefits outweigh known and potential risks for the intended indication and population. The resulting approval is tied to a label: a particular cancer type, disease stage or treatment setting, biomarker definition, dose, schedule, and sometimes a required diagnostic test.
Approval does not mean that every patient with cancer benefits, that every tumor carrying a related alteration will respond, or that the drug is appropriate outside the labeled circumstances. Evidence may be strongest in a narrowly defined subgroup and weaker in other cancers or lines of therapy.
FDA’s development and approval overview describes review of the application, manufacturing information, clinical evidence, labeling, and post-approval obligations. Manufacturing consistency and the ability to produce the drug reliably are part of the regulatory decision, alongside clinical benefit and safety.
What happens after approval?
Post-approval work can continue to clarify long-term safety, effectiveness in additional groups, drug interactions, and outcomes in routine practice. For an accelerated approval, the sponsor must complete confirmatory studies under the applicable requirements. New evidence can lead to label changes, additional indications, restrictions, or other regulatory decisions.
Free tools Windows power users keep installed
One-click scans. No signup required.
How should two targeted-drug programs be compared?
Comparing programs by phase number alone is misleading. A more useful comparison asks:
| Comparison question | Why it matters |
|---|---|
| Which biomarker and assay define eligibility? | A similar-sounding alteration may be detected by different tests, thresholds, or sample types. |
| Which cancer type and treatment setting are studied? | Prior treatments, disease stage, and tumor biology affect both expected benefit and risk. |
| What is the trial design? | Randomization and a concurrent comparator generally provide a stronger basis for direct treatment comparisons than a small single-arm cohort. |
| What endpoint and follow-up are reported? | Response rate without duration, survival follow-up, or patient-reported outcomes gives an incomplete picture. |
| Who was enrolled? | Age, prior therapy, organ function, performance status, and biomarker prevalence affect how broadly results apply. |
| Which approval route and confirmatory evidence apply? | Traditional approval and accelerated approval carry different levels of remaining uncertainty and post-approval obligations. |
When reading a study report or regulatory announcement, check the protocol-defined population and endpoint before drawing conclusions. A compelling result in one biomarker-selected cohort may not transfer to a different assay, tumor type, or treatment line.
Also popular on Amazon
- 【Read before You Buy】 Note: This adapter is USB 2.0 version and cannot transmit HDM, VGA, or other video signals. Nevertheless, they are fully capable of charging devices,duplicating files, and can be seamlessly integrated with USB-C earphones, wireless network adapters, and SD card adapters.
- 【Easy to Use and Safe】Thanks to modern manufacturing techniques, we've made these adapters sufficiently compact so that they can remain inserted in your device without noticeable protrusion or inconvenience. This means you don't have to constantly plug and unplug them, reducing the likelihood of wear and misalignment, and making them more convenient to carry around.
- 【Reliable Quality】Engineered for enhanced durability, durable aluminum alloy shell material,get excellent wear resistance and heat dissipation,the male USB C and female USB connectors & the male USB and female USB C connectors are designed to be plugged and unplugged up to 20000 times. Provides data transfer, device charging, memory space expansion, and additional computer peripherals.
- 【Think more for you】Do you need to connect a USB-C-enabled device to an odd device that only has USB-A ports? Then these USB-A male to USB-C female adapters are made for you.Simply insert the adapter into the USB-A port on the device, and you can instantly connect your USB-C device to the device that originally didn't have the correct connection port.
- 【Trusted xiwxi Quality and Service】As a responsible brand seller, you will receive xiwxi's 12-month Quality assurance and lifetime friendly customer service, you're not just buying a product,you're investing in peace of mind with all-round quality and exceptional customer service.
Why is there no universal timeline or patient count?
Drug development duration depends on the disease, target, recruitment rate, manufacturing readiness, observed safety, endpoint maturity, and regulatory pathway. Rare biomarkers can make enrollment slow, while common cancers may support larger randomized studies. Some programs pause, redesign, add cohorts, or stop when the risk–benefit outlook changes.
Likewise, FDA’s phase descriptions provide typical patterns rather than fixed minimums that every drug must satisfy. A small early study can generate a hypothesis; a larger, well-controlled study is usually needed to establish how reliably the treatment helps the intended population. The evidentiary strength comes from the design, data quality, follow-up, and consistency of results—not from the phase label alone.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →What should a reader ask when seeing a new targeted-drug result?
- What exactly was targeted? Identify the molecular alteration, pathway, and assay used.
- Who received the drug? Note cancer type, treatment line, prior therapies, biomarker cutoff, and key exclusions.
- Was there a comparator? A randomized control provides context that a single-arm response percentage cannot.
- Which endpoint improved, and for how long? Separate response, duration, progression-free survival, overall survival, symptoms, and quality of life.
- What approval status applies? Check the labeled indication, whether approval was accelerated, and whether confirmatory evidence is complete.
- What remains uncertain? Look for limited follow-up, small subgroups, treatment cross-over, missing data, or resistance mechanisms.
These questions turn a headline about a “precision” or “targeted” treatment into a more precise assessment of what the evidence actually establishes.
Frequently Asked Questions
Do all first-in-human cancer trials test a drug in people with the matching biomarker?
No. Some early protocols enroll broadly and collect tumor samples for exploratory analyses, while others require a biomarker from the outset. Eligibility depends on the drug’s mechanism, available assay, and the scientific question in that protocol.
Can a targeted drug be approved for more than one cancer type?
Yes, if evidence supports separate indications or a tissue-agnostic indication under the applicable regulatory standard. Each use still has its own defined population, biomarker requirements, dose, and supporting evidence.
Why can a tumor respond and then become resistant to a targeted drug?
Cancer cells can acquire new mutations, lose the original target, activate alternate signaling routes, or contain resistant subclones from the start. Trials may analyze repeat biopsies or circulating biomarkers to investigate these mechanisms.
Where can I find the exact eligibility rules for a clinical trial?
The study record and protocol listing provide the authoritative inclusion and exclusion criteria, required biomarker assay, treatment history, dosing schedule, and primary endpoints. Criteria can change when a protocol is amended, so readers should check the current record.

